Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Advances in the development of corticotropin-releasing-hormone (CRH) receptor agonists as candidate analgesics

21 Sep 04

It has been estimated that 9% of the US population suffers from moderate to severe non-cancer-related pain. Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year and the development of analgesics represents a major pharmaceutical objective. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within t
LeadDiscovery

Developing therapeutic agents for the treatment of early (premature) ejaculation

21 Sep 04

Early ejaculation represents a major market, and indeed in 18-65 year olds it represents the predominant sexual dysfunction, affecting at least 20% of men. The global annual market for the treatment of early ejaculation has been estimated at $4 billion. However due to the absence of readily available therapeutics fewer than 10% of patients seek treatment for early ejaculation. Successful pharmaceutical development in this field may therefore reap immense rewards. Drug development has however bee
LeadDiscovery

Fujisawa's FK-866 reduces the growth and vascularization of renal cell carcinomas and also tumor metastasic

21 Sep 04

Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the US and 12,000 patients die of the disease annually. The market is currently dominated by the cytokines, but there is significant interest among physicians in the potential of anti-angiogenics, particularly so since renal cell carcinomas are known to be well vascularized. Researchers have now show
LeadDiscovery

Development of anti-CD154 monoclonal antibodies for the prevention of transplant rejection

21 Sep 04

The recent success of monoclonal antibody therapies such as Genentech's Rituxan and Johnson & Johnson's Remicade are driving further development of this field. MAb therapies brought in revenues of over $5.1 billion in 2003, a figure which should nearly triple over the next five years as new MAbs are launched and following the approval of new indications for MAbs already on the market. By 2008, MAbs should account for 32 percent of all revenue in the biotech market. One therapeutic antibody indic
LeadDiscovery

IL-27 as an exciting new target for cancer immunotherapy

21 Sep 04

In 2002 nearly 1,285,000 new cancer cases were diagnosed in the United States, and due to the lack of options for the treatment of advanced disease more than 550,000 Americans died of the disease. Immunotherapy represents an emerging approach to the treatment of cancer that promises high specificity with negligible side effects. This approach to cancer treatment commonly involves the stimulation of T cells and antibody production and the use of cytokines has been extensively studied. IL-12 has b
LeadDiscovery

Berlex researchers develop lipoxin A4 (LXA4) mimics for the treatment of inflammation

21 Sep 04

Treatments for inflammatory diseases comprise a $20 billion market spanning diseases such as psoriasis, asthma, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Both the prostaglandins and the leukotrienes are involved in the initiation and maintenance of inflammatory responses however agents that center on these mediators have produced limited therapeutic efficacy in various inflammatory disease settings. Harnessing the properties of anti-inflammatory mediators such as l
LeadDiscovery

Emerging Drug Discovery Targets: 21st September

21 Sep 04

Emerging Drug Discovery Targets provides a regular summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. Information includes editorials on recently published journal articles, selected press releases and "intelligence reports". This edition features an LXA4 mimic for the treatment of inflammation; IL-27 as a cancer immunotherapy; anti-CD154 for organ transplant; CRH agonists for the treatment of pain; and an effective therapy
LeadDiscovery

PharmaNews Bytes: Selected September press releases from the pharma/biotech sector

17 Sep 04

LeadDiscovery's intelligence service, DailyUpdates has evolved as a key tool to help all in the drug development sector keep track of breaking journal articles, press releases and pharmaceutical reports. Pharma NewsBytes features selected press releases recently featured on DailyUpdates and offers the reader a leisurely stroll through the past few weeks of activity from within the pharmaceutical industry.
LeadDiscovery

GlaxoSmithKline's IkappaB kinase 2 (IKK-2) inhibitor, TCPA-1 as a potential next generation disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis

15 Sep 04

The TNF blockers Enbrel (etanercept) and Remicade (infliximab), have contributed to a revolution in the treatment of rheumatoid arthritis. The drug development community is now expending considerable resources on developing next generation disease modifying antirheumatic drugs (DMARDs) with improved efficacy and safety as well as oral activity. GlaxoSmithKline's IkappaB kinase 2 (IKK-2) inhibitor, TCPA-1 has recently been developed and has shown considerable promise in early stage development.
LeadDiscovery

Patient compliance is a $30 billion complaint

13 Sep 04

We all forget to take medication from time to time, or maybe even don't bother to refill our prescriptions because we're feeling fine. However, the cumulative effect of all this is costing the pharmaceutical industry in excess of $30 billion a year. Datamonitor's Adele Schulz offers pharmaceutical companies some practical solutions to help stop the financial bleeding...
Datamonitor

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.